About This Review
This review covers Pfizer’s worldwide business and provides information on our activities for the year ending on December 31, 2021. It describes key dimensions of our purpose, strategy, and performance as well as analysis of trends and strategies for addressing Environment, Social, and Governance (ESG) key performance indicators. The ESG Report, in which this information is supplied, is available for download via link in the footer of this report.
Forward Looking Information
This Annual Review contains forward-looking statements about, among other topics, our anticipated operating and financial performance, business plans, strategy, and prospects, expectations for our product pipeline, in-line products and product candidates, including anticipated regulatory submissions, data read-outs, study starts, approvals, clinical trial results and other developing data, revenue contribution, growth, performance, timing of exclusivity, potential benefits and breakthrough, best-in-class, first-in-class or blockbuster status, strategic reviews, capital allocation objectives, dividends and share repurchases, reorganizations, plans for and prospects of our acquisitions, dispositions and other business-development activities and our ability to successfully capitalize on these opportunities, manufacturing and product supply, our efforts to respond to COVID-19, including the Pfizer-BioNTech mRNA vaccine for COVID-19 and our oral COVID-19 treatment (Paxlovid™), our expectations regarding the impact of COVID-19 on our business, operations and financial results and our ESG strategy that are subject to substantial risks and uncertainties. We cannot guarantee that any forward-looking statement will be realized. Should known or unknown risks or uncertainties materialize or should underlying assumptions prove inaccurate, actual results could vary materially from past results, future plans and projected future results.
A further list and description of risks, uncertainties and other matters can be found in Pfizer's Annual Report on Form 10-K for the year ended December 31, 2021, and in Pfizer's subsequent reports on Form 10-Q, in each case including in the sections thereof captioned “Risk Factors” and “Forward-Looking Information and Factors That May Affect Future Results,” as well as in Pfizer's subsequent reports on Form 8-K. These reports are available on our website at www.pfizer.com and on the U.S. Securities and Exchange Commission's (SEC) website at www.sec.gov. The forward-looking statements in this Annual Review speak only as of the original date of this Annual Review, and we undertake no obligation to update or revise any of these statements as the result of new information or future events or developments or otherwise.
Data in this review and associated ESG Report covers the calendar year from January 1 to December 31, 2021, unless otherwise stated.
Unless otherwise noted herein, the trademarks, logos and service marks appearing in the Annual Review, whether or not appearing with the trademark symbol, are owned or licensed by Pfizer Inc. or its affiliates.
Myfembree® is a registered trademark of Myovant Sciences GmbHPanzyga® is a registered trademark of Octapharma AG Bavencio® is a registered trademark of Merck KGaA.